- Home
- HSCS vs IMNN Comparison
HSCS vs IMNN Comparison
Compare HSCS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | IMNN |
|---|---|---|
| Founded | 2007 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 11.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | HSCS | IMNN |
|---|---|---|
| Price | $2.58 | $3.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.20 | ★ $182.61 |
| AVG Volume (30 Days) | 8.0K | ★ 17.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,072.41 | N/A |
| Revenue Next Year | $2,700.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $0.37 |
| 52 Week High | $6.47 | $9.32 |
Technical Indicators
Market Signals| Indicator | HSCS | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 43.18 |
| Support Level | $2.16 | $3.03 |
| Resistance Level | $3.28 | $3.16 |
| Average True Range (ATR) | 0.11 | 0.23 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.45 | 23.73 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).